How many drugs treat Pulmonary tuberculosis?

Drug Landscape tracks 10 marketed treatments for Pulmonary tuberculosis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pulmonary-tuberculosis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pulmonary tuberculosis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pulmonary tuberculosis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pulmonary tuberculosis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Sirturo	bedaquiline	Janssen Therap	Diarylquinoline Antimycobacterial	Potassium voltage-gated channel subfamily H member 2	2012-01-01
Priftin	RIFAPENTINE	Sanofi	Rifamycin Antimycobacterial [EPC]		1998-01-01
Capastat Sulfate	CAPREOMYCIN	Epic Pharma Llc	Antimycobacterial		1971-01-01
Pyrazinamide	PYRAZINAMIDE	Dava Pharms Inc	Antimycobacterial [EPC]	Cytochrome P450 3A4	1971-01-01
Rifadin	Rifampicin	Sanofi Aventis Us	Rifamycin Antibacterial [EPC]	Solute carrier organic anion transporter family member 1A2, ATP-binding cassette sub-family G member 2, Alpha-synuclein	1971-01-01
Myambutol	ETHAMBUTOL	Kanchan Hlthcare	Antimycobacterial	Cytochrome P450 3A4	1967-01-01
Trecator	ETHIONAMIDE	Pfizer	Antimycobacterial		1965-01-01
Cyclorin	CYCLOSERINE	Purdue Gmp	cycloserine	Glutamate receptor ionotropic, NMDA 2A	1964-01-01
Isoniazid	ISONIAZID	Epic Pharma Llc	Antimycobacterial [EPC]	Myeloperoxidase	1952-01-01
Apacil	AMINOSALICYLATE SODIUM	Consolidated Midland	aminosalicylic acid	Tyrosine-protein phosphatase non-receptor type 1	1950-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Pulmonary tuberculosis
Consolidated Midland · 2 drugs in Pulmonary tuberculosis
Epic Pharma Llc · 2 drugs in Pulmonary tuberculosis
Dava Pharms Inc · 1 drug in Pulmonary tuberculosis
Janssen Therap · 1 drug in Pulmonary tuberculosis
Kanchan Hlthcare · 1 drug in Pulmonary tuberculosis
Massachusetts General Hospital · 1 drug in Pulmonary tuberculosis
Pfizer · 1 drug in Pulmonary tuberculosis
Purdue Gmp · 1 drug in Pulmonary tuberculosis
Sanofi · 1 drug in Pulmonary tuberculosis
Sanofi Aventis Us · 1 drug in Pulmonary tuberculosis
BRISTOL MYERS SQUIBB · 1 drug in Pulmonary tuberculosis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pulmonary tuberculosis:

Cite this brief

Drug Landscape (2026). Pulmonary tuberculosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pulmonary-tuberculosis. Accessed 2026-06-10.

Pulmonary tuberculosis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing